|
|
Article: Studies from Mayo Clinic yield new information about irritable bowel syndrome therapy.
- Article from:
- Biotech Week
- Article date:
- April 8, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Scientists discuss in 'Pharmacogenetics of low dose clonidine in irritable bowel syndrome' new findings in irritable bowel syndrome. According to recent research published in the journal Neurogastroenterology & Motility, "Adrenergic and serotonergic (ADR-SER) mechanisms alter gut (gastrointestinal, GI) sensorimotor functions. We aimed to determine whether candidate ADR-SER genes affect GI responses to low dose clonidine (CLO) in humans."
"Forty healthy and 120 irritable bowel syndrome (IBS) participants received CLO, 0.1 mg or 0.15 mg b.i.d., for 6 days. At baseline and post-CLO, we measured: gastric volume (GV); satiation volume; rectal compliance, sensation ...